U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880562) titled 'The RESPLASH Study' on March 11.
Brief Summary: To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Resistant Hypertension
Intervention:
DEVICE: Splanchnic Nerve Denervation
Catheter-based endovascular denervation (CDN) of renal arteries and splanchnic nerves (celiac + SMA) using radiofrequency ablation
DEVICE: Renal Denervation Only
Catheter-bas...